135 related articles for article (PubMed ID: 24442426)
21. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients.
Ranieri G; Ammendola M; Marech I; Laterza A; Abbate I; Oakley C; Vacca A; Sacco R; Gadaleta CD
World J Gastroenterol; 2015 May; 21(19):6018-25. PubMed ID: 26019468
[TBL] [Abstract][Full Text] [Related]
22. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
23. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization.
Hsieh MY; Lin ZY; Chuang WL
Kaohsiung J Med Sci; 2011 Aug; 27(8):314-22. PubMed ID: 21802642
[TBL] [Abstract][Full Text] [Related]
24. HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Pinto E; Pelizzaro F; Cardin R; Battistel M; Palano G; Bertellini F; Kitenge MP; Peserico G; Farinati F; Russo FP
Dig Liver Dis; 2024 May; 56(5):872-879. PubMed ID: 37783655
[TBL] [Abstract][Full Text] [Related]
25. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study.
Poon RT; Lau C; Yu WC; Fan ST; Wong J
Oncol Rep; 2004 May; 11(5):1077-84. PubMed ID: 15069550
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
[TBL] [Abstract][Full Text] [Related]
27. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.
Yoo JJ; Lee JH; Lee SH; Lee M; Lee DH; Cho Y; Lee YB; Yu SJ; Kim HC; Kim YJ; Yoon JH; Kim CY; Lee HS
PLoS One; 2014; 9(11):e113926. PubMed ID: 25427152
[TBL] [Abstract][Full Text] [Related]
30. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
31. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic significance of serum level of vascular endothelial growth factor receptor-2 in hepatocellular carcinoma patients after transcatheter arterial chemoembolization].
Meng QW; Li Y; Hu BS; Shao PJ; Zhan MX; Yu XY; Lu LG
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(5):341-4. PubMed ID: 23660204
[TBL] [Abstract][Full Text] [Related]
33. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Zhan M; Li Y; Hu B; He X; Huang J; Zhao Y; Fu S; Lu L
J Vasc Interv Radiol; 2014 Aug; 25(8):1279-1287.e1. PubMed ID: 24935355
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.
Yoon SM; Ryoo BY; Lee SJ; Kim JH; Shin JH; An JH; Lee HC; Lim YS
JAMA Oncol; 2018 May; 4(5):661-669. PubMed ID: 29543938
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
[TBL] [Abstract][Full Text] [Related]
36. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.
Shim JH; Kim KM; Lee YJ; Ko GY; Yoon HK; Sung KB; Park KM; Lee SG; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
Ann Surg Oncol; 2010 Mar; 17(3):869-77. PubMed ID: 20033326
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.
Pokuri VK; Tomaszewski GM; Ait-Oudhia S; Groman A; Khushalani NI; Lugade AA; Thanavala Y; Ashton EA; Grande C; Fetterly GJ; Iyer R
Am J Clin Oncol; 2018 Apr; 41(4):332-338. PubMed ID: 27014931
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
39. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A retrospective analysis of 509 cases.
Shen H; Zheng S; Chen R; Jin X; Xu X; Jing C; Lin J; Zhang J; Zhang M; Zhang L; Xie X; Guo K; Ren Z; Lin S; Zhang B
Medicine (Baltimore); 2017 Jul; 96(28):e7438. PubMed ID: 28700480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
